NASHVILLE, Tenn. / Aug 30, 2023 / Business Wire / HCA Healthcare, Inc. (NYSE:HCA), is scheduled to present at the following healthcare conference:
September 12, 2023 at 9:30 am EDT at the Morgan Stanley 21st Annual Global Healthcare Conference held at the Sheraton New York in New York, NY.
A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company’s website, www.hcahealthcare.com.
Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company’s website for the latest information.
About HCA Healthcare
Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 182 hospitals and approximately 2,300 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom.
All references to “Company” and “HCA” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.
| Last Trade: | US$333.00 |
| Daily Change: | -2.11 -0.63 |
| Daily Volume: | 1,355,338 |
| Market Cap: | US$84.350B |
October 25, 2024 October 17, 2024 July 23, 2024 April 26, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
